← Leaderboards
Patrick J Grohar
Van Andel Research Institute
$5,442,465
Attributed
$5,442,465
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $853K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,442,465 · 3
By mechanism
R01$3,433,634 · 2
U01$2,008,831 · 1
Top collaborators
No co-investigators on record.
Most similar at Van Andel Research Institute
Same institution · by research overlap
- Maggie Chasse$535,640
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsClinicTumorEws-Fli1 Fusion ProteinCell NucleusEwings SarcomaTranscription FactorTranslatingCellsCell SurvivalGenetic TranscriptionDrug ResistanceCell NucleolusGenesPharmaceutical PreparationsFli1 Transcription FactorDoseMutationDependenceNeoplasm MetastasisInsightIn VivoChromosomal Translocation22)(Q24
Grant awards (15)
The interface of transcription, DNA damage and epigenetics: A therapeutic vulnerability of the EWS-FLI1 transcription factor$459,648
R01 · FY2025 · CA · contact PI
The interface of transcription, DNA damage and epigenetics: A therapeutic vulnerability of the EWS-FLI1 transcription factor$390,028
R01 · FY2024 · CA · contact PI
The interface of transcription, DNA damage and epigenetics: A therapeutic vulnerability of the EWS-FLI1 transcription factor$47,212
R01 · FY2024 · CA · contact PI
The interface of transcription, DNA damage and epigenetics: A therapeutic vulnerability of the EWS-FLI1 transcription factor$505,743
R01 · FY2023 · CA · contact PI
A collaborative approach to analyze and target the EWS-FLI1 transcription factor in patients with Ewing sarcoma$111,060
U01 · FY2023 · CA · contact PI
A collaborative approach to analyze and target the EWS-FLI1 transcription factor in patients with Ewing sarcoma$571,948
U01 · FY2022 · CA · contact PI
A collaborative approach to analyze and target the EWS-FLI1 transcription factor in patients with Ewing sarcoma$357,335
U01 · FY2021 · CA · contact PI
A collaborative approach to analyze and target the EWS-FLI1 transcription factor in patients with Ewing sarcoma$494,871
U01 · FY2020 · CA · contact PI
A collaborative approach to analyze and target the EWS-FLI1 transcription factor in patients with Ewing sarcoma$473,617
U01 · FY2019 · CA · contact PI
Development of Trabectedin Analogs that Target the EWS-FLI1 Transcription Factor$351,468
R01 · FY2019 · CA · contact PI
Development of Trabectedin Analogs that Target the EWS-FLI1 Transcription Factor$27,959
R01 · FY2019 · CA · contact PI
Development of Trabectedin Analogs that Target the EWS-FLI1 Transcription Factor$391,163
R01 · FY2018 · CA · contact PI
Development of Trabectedin Analogs that Target the EWS-FLI1 Transcription Factor$391,163
R01 · FY2017 · CA · contact PI
Development of Trabectedin Analogs that Target the EWS-FLI1 Transcription Factor$434,625
R01 · FY2016 · CA · contact PI
Development of Trabectedin Analogs that Target the EWS-FLI1 Transcription Factor$434,625
R01 · FY2015 · CA · contact PI